Apuli Maricel's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Aug 18, 2026
- Accession no.
- 0001470831-26-000835
- Filed
- Aug 18, 2026, 6:02 PM ET
- Trade date
- Aug 16, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Apuli MaricelCIK 0002058197 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2026 | Common Stock | FTax withholdingDisposed | −4,714 | $79.86 | −$376,460.04 | 122,687 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.